Plasma concentrations of apolipoproteins A-I, B and M in patients with abdominal aortic aneurysms.
OBJECTIVE
Apolipoproteins play important roles in the development of atherosclerosis but their involvement in the pathogenesis of abdominal aortic aneurysm (AAA) is poorly understood. The aim was to investigate whether apoA-I, apoB and apoM are independently associated with AAA.


METHODS
Plasma apoA-I, apoB and apoM were measured in 343 patients with AAA and in 214 elderly apparently healthy control individuals from the background population.


RESULTS
AAA patients had lower apolipoprotein levels, as compared to healthy individuals: apoA-I, 1.62 vs. 2.08 g/L; apoB, 0.91 vs. 1.04 g/L; apoM, 0.72 vs. 0.91 mumol/L (p<0.0001 for all three). In multivariate analyses, apoA-I and apoB were associated with AAA, odds ratios (95% confidence intervals) being 0.53 (0.43-0.64) and 0.86 (0.75-0.998), respectively.


CONCLUSIONS
ApoA-I, apoB and apoM levels were significantly lower in patients with AAA than in the control individuals, but only apoA-I and apoB were independently associated to AAA.
Ahnström
Josefin
J
Wallenberg Laboratory, Department of Laboratory Medicine, Clinical Chemistry, Lund University, SE-205 02 Malmö, Sweden.
Gottsäter
Anders
A
Lindblad
Bengt
B
Dahlbäck
Björn
B
D000368:Aged; D017544:Aortic Aneurysm, Abdominal / Q000097:blood* / Q000188:drug therapy; D016632:Apolipoprotein A-I / Q000097:blood*; D001053:Apolipoproteins / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood*; D000075243:Apolipoproteins M; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D054834:Lipocalins; D016015:Logistic Models; D008297:Male; D015999:Multivariate Analysis
C400523:APOM protein, human; D016632:Apolipoprotein A-I; D001053:Apolipoproteins; D001055:Apolipoproteins B; D000075243:Apolipoproteins M; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D054834:Lipocalins